MDX-1303 is a fully human antibody against the inhalation anthrax, the most lethal form of illness in humans caused by the Bacillus anthracis bacterium, and targets a protein component of...
- Mechanism
- Curator reviewed
MDX-1303 targets a protein component of lethal toxins produced by the bacterium known as the anthrax protective antigen. The anthrax protective antigen initiates the onset of the illness by attaching to cells in the infected person, and then facilitates the entry of additional destructive toxins into the cells. MDX-1303 is designed to target anthrax protective antigen and protect the cells from damage by the anthrax toxins.
- Primary indication
- Investigated for use/treatment in anthrax exposure and bacterial infection.Curator reviewed
- Also known as
- IMMUNOGLOBULIN, ANTI-(BACILLUS ANTHRACIS ANTHRAX PROTECTIVE ANTIGEN) (HUMAN MONOCLONAL 5E8 HEAVY CHAIN), DISULFIDE WITH HUMAN MONOCLONAL 5E8 LIGHT CHAIN, DIMER · MAb-1303
- Code names
- MDX-1303
Resolves to
What you can answer from here — as of June 15, 2026
Which drugs share a target with MDX-1303, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account